Navigation Links
FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
Date:12/21/2007

BERKELEY HEIGHTS, N.J., Dec. 21 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced today that the Company has received notice from the Food and Drug Administration (FDA) that FDA has extended its review period of Genta's request for correction of certain information that was filed pursuant to the Information Quality Act for an additional 60 days. The requested correction relates to FDA's assessment of progression-free survival (PFS) in the Phase 3 trial of Genasense(R) (oblimersen sodium injection) that was presented to the Oncology Drug Advisory Committee (ODAC) that considered Genta's New Drug Application for Genasense in patients with advanced melanoma.

"Melanoma is a key indication in our current Phase 3 development program", said Dr. Loretta M. Itri, M.D., Genta's President for Pharmaceutical Development and Chief Medical Officer. "A methodological error may have impacted ODAC deliberations, which voted unanimously that an improvement in PFS of some magnitude represents clinical benefit that could support regular approval in advanced melanoma."

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusivel
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
4. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
5. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
6. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
7. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
10. GlaxoSmithKline Accelerates Review of Exelixis XL880
11. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...E, Minn., Dec. 3 Upsher-Smith Labo...ts strategic plan for central nervous system (CNS)...), an internally developed program for the managem...sher-Smith,s proprietary formulation technology an...010 for the adjunctive treatment of epilepsy patie...
(Date:12/3/2009).... 3 Amira Pharmaceuticals, Inc. ... 1 clinical study of AM461, the Company,s second o... CRTH2) receptor. ,, The interim results demo...PD) effect can be achieved with AM461. Additional... safety profile. AM461 is a back-up to Amira,s le...
(Date:12/3/2009)...INGTON, Dec. 3 Centra...y reported that the " Help is Here Express " bus...ally-struggling Floridians access information on p...on medicines for free or nearly free. ,, The "...artnership for Prescription Assistance ( PPA ) an...
Breaking Medicine Technology:Upsher-Smith Announces Milestone in Development of CNS Strategy 2Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira's Lead DP2 Antagonist, AM211 2'Help is Here Express' in Orlando to Help Floridians Afford Medicine 2CBay Announces the Reseller Partnership Program 49146 1CBay Announces the Reseller Partnership Program 49146 2Wisconsin Doctor Raj Ambay Elected to the AMA Board of Trustees 49142 1Wisconsin Doctor Raj Ambay Elected to the AMA Board of Trustees 49142 2VIDEO from Medialink and Siemens 3A New Treatment in Breast Cancer Detection 49138 1
...Treated With ENB-0040 at Children,s Hospital, Heal...Dec. 1 Enobia Pharma, an emerging Canadian biotec... for serious bone disorders, today announced that ...or hypophosphatasia was dosed. Enobia is investiga...0 for the treatment of this rare and often crippli...
...Genaera Corporation (Nasdaq: GENR ) today announ...-1436C-102 (Study 102), the multiple ascending dos...erweight and obese type 2 diabetics. MSI-1436 is a...betes and obesity which works centrally and periph...ough the highly selective inhibition of its novel ...
Other Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3
(Date:12/3/2009)...hat children exposed to smoke are at risk of lung ...ews) -- Add colorectal cancer to the list of malig...thening the link between the two. , And other s...haven,t managed to quit: Two papers published in t...p; Prevention , a themed issue on tobacco, strengt...
(Date:12/3/2009)...etes: A Deeper Look Educates Americans About Th...r All Ages ,, DETROIT, Dec. 3 /PRNewswire-USN...nosed with diabetes every 21 seconds. On December ... newest exhibit, Diabetes: A Deeper Look, to hel...t diabetes, diabetes treatment and the role insuli...
(Date:12/3/2009)...N, Dec. 3 Three US Oncology, Inc ...Record Award in the Occupational Safety & Heal...nce inception in 2005, US Oncology Specialty, LP ...tribution center; and OncologyRx Care Advantage(T...ved the Occupational Excellence Award from the nat...
(Date:12/3/2009)...teers from virus linked to cervical cancer , ...uman papillomavirus (HPV) vaccine Cervarix protect...new research has found. , The vaccine guards ag...t commonly associated with cervical cancer. , T..., with a normal cervical profile and no evidence o...
(Date:12/3/2009)...or Practices, Protecting Donors, and Blood Safety ...e-USNewswire/ -- Teamsters who work at American Re...lphia went on strike this morning to protest unfai...ions at these facilities that could imperil the sa...ly, not to mention the wellbeing of employees. ,...
Breaking Medicine News(10 mins):Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 2Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 3Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 4Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 2Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 3Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 4Health News:US Oncology Celebrates Consecutive Safety 2Health News:US Oncology Celebrates Consecutive Safety 3Health News:Cervarix Proves Effective Against HPV for Over 6 Years 2Health News:Philadelphia Red Cross Blood Workers Strike to Protect Donor and Blood Safety 2
...SDALE, Ariz., Nov. 19 Changing Times,Vitamins, In...have signed a,licensing agreement with King Featur...of the nation,s largest diversified media companie... for sale,and promotion of these products. CTV pre...
...APOLIS, Nov. 19 Ellie Peterson, inspirer and,pres...he arrival of her book,on how a "life gone hard" c...,Movements(TM) is the companion to her Power of Po...ne, then explains the victory over her greatest,en...
...cade Since the Master Settlement Agreement, Cigare...rth , , WASHINGTON,Nov. 19 New data from the...n in the U.S. has decreased by an estimated 28 per...ssociation of Attorneys General (NAAG) and the Ame...
...,s First National Cervical Cancer Screening Progra... In a campaign to significantly reduce the most ... Public Health Agency (Secretaria de Salud) announ... cancer, to all low-income women age 35-65. In the...
...IEGO, Nov. 19 Naviscan, Inc., announced today tha...granted 510(k) clearance for,its biopsy-guidance f...resolution organ-specific PET scanner. The scanne...alization of lesions in female breasts, as identif...
...T. Mayberry Decides to Step Down as Chairman , ...Inc. (TSX: MDS; NYSE: MDZ ), a leading provider ...es markets, today announced the appointment of Jam... the MDS Board since July 2005. John T. Mayberry, ...
Other Medicine News:Health News:King Features Syndicate and Changing Times Vitamins Sign Licensing Agreement for Popeye(R) the Sailor Man in the Water Drink Category. 2Health News:King Features Syndicate and Changing Times Vitamins Sign Licensing Agreement for Popeye(R) the Sailor Man in the Water Drink Category. 3Health News:Meditative Movements(TM), State-of-the-Art Fitness Guidebook, Now Available 2Health News:America Reaches Major Anti-Smoking Milestone 2Health News:America Reaches Major Anti-Smoking Milestone 3Health News:America Reaches Major Anti-Smoking Milestone 4Health News:America Reaches Major Anti-Smoking Milestone 5Health News:Mexican Department of Public Health to Launch Screening for Papillomavirus, Cause of Cervical Cancer 2Health News:Mexican Department of Public Health to Launch Screening for Papillomavirus, Cause of Cervical Cancer 3Health News:Naviscan Receives 510(k) Clearance for Stereo Navigator(TM) - the First Commercially Available Breast PET-Guided Biopsy Feature 2Health News:MDS Inc. Announces Appointment of James S.A. MacDonald as Chairman of Board of Directors 2
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
Medicine Products: